What’s Next For PanOptica? We Ask CEO Paul Chaney

PanOptica's game-changing treatment for AMD and DR

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 157″]

CEO Paul Chaney details the company’s plans to move forward with $11 million in new capital. He also recounts how his unplanned entry into ophthalmology led him to appreciate how special the specialty truly is. Chaney also explains why PanOptica’s pursuit of an eye-drop-based treatment for AMD and DR is personal.

Learn more about Paul Chaney here.